Vaccibody and Adaptive Biotechnologies sign license agreement on SARS-CoV-2 T-cell epitopes July 13, 2021
Boehringer chases rival Merck KGaA with research into IAP cancer drugs June 25, 2021 By Richard Staines Boehringer Ingelheim GmbH has begun a three-year collaboration with researchers at Australia’s WEHI, looking into a potentially powerful approach to targeted protein degradation also being studied by its German rival Merck KGaA.Read More
Kite and ShoreLine Biosciences partner on allogeneic cell therapies for hematologic malignancies June 18, 2021
RSS